Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst. We consider the cutting-edge enzyme producer well positioned for growth and see the current share price at an attractive level for a rapidly expanding compounder with compelling optionality.
Lähde: Finwire News
Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.